Gilead Sciences, Inc. (GILD) – Can Gilead revive from its recent fall?
in Company Report , Healthcare & Life Sciences , Pharma & Biotech on March 24, 2022In 2021, the company received seven approvals or accelerated approvals in the US and Europe. Company’s 2022 plans include a significant increase in clinical development studies across its novel
oncology portfolio.
Highlights
Valuation
– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– Discounted Cash Flow Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum
Actual & Historical Performance
– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Key Metrics
– M&A Deals
Peer Performance
– Summary
– Profitability
– Growth
– Price Performance
Ownership
Stock Price Performance
Crispidea Coverage
No of Pages : 37
Recent Blog Posts
Related Products
Popular & Trending
Featured Products
